SANTA CLARA, Calif., October 12, 2022 Agilent Technologies Inc. (NYSE: A) today announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the core of Agilent’s dissolution business, including research and development, quality, support, applications, marketing, and more. This investment allows all Agilent dissolution... Read more
Increased testing capacity will provide greater understanding of microplastics contamination in the environment SANTA CLARA, Calif., October 03, 2022 Agilent Technologies Inc. (NYSE: A) today announced the release of its enhanced 8700 LDIR Chemical Imaging System, which has been further optimized for the analysis of microplastics in environmental samples. This newly improved package includes Clarity 1.5... Read more
SANTA CLARA, Calif., August 02, 2022 Agilent Technologies Inc. (NYSE: A), today announced it has acquired Polymer Standards Service GmbH (PSS) a provider of solutions in the field of polymer characterization. PSS specializes in hardware and software solutions used in defining the makeup and creation of molecular structures. The company provides complete solutions for gel permeation chromatography... Read more
BANGKOK, Thailand June 13, 2022 BANGKOK, Thailand–(BUSINESS WIRE)– Agilent Technologies Inc. (NYSE: A) today announced the signing of a Memorandum of Understanding (MOU) with Mahidol University in Thailand to accelerate research and development (R&D) in the field of science over the next three years. The MOU with the university’s Faculty of Science supports a newly established set... Read more
SANTA CLARA, Calif., October 21, 2021 Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and... Read more
SANTA CLARA, Calif., October 13, 2021 Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.... Read more
Pfizer executive brings strong scientific and medical expertise to Agilent board SANTA CLARA, Calif., September 23, 2021 Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to Agilent’s board of directors, effective Sept. 21, 2021. Dr. Dolsten brings... Read more
Customers will benefit from reduced delivery time for next generation sequencing (NGS) products SANTA CLARA, Calif., August 03, 2021 Agilent Technologies Inc. (NYSE: A) today announced that it has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China. Agilent is a leading provider of next-generation sequencing assays, and customers often develop... Read more
Launching the full range for biopharma analysis at the Agilent InfinityLab LC Virtual Conference SANTA CLARA, Calif., June 22, 2021 Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the Agilent portfolio of complete Bio LC solutions,... Read more
SANTA CLARA, Calif., April 20, 2021 Agilent Technologies (NYSE: A) today was named one of the top U.S. companies for diversity, marking the third straight year it has been recognized for its commitment to fostering a diverse and inclusive workplace. Specifically, Agilent ranked No. 83 out of 500 companies on Forbes’s 2021 list of America’s Best Employers... Read more